Glasgow – Confidence in Concept 2019
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Publications
Cooke SF
(2024)
Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC.
in Scientific reports
Dickson-Murray E
(2021)
The Mia40/CHCHD4 oxidative folding system: Redox regulation and signalling in the mitochondrial intermembrane space
in Antioxidants
Dunlea T
(2023)
Healthcare provider-focused antimicrobial stewardship in sub-Saharan Africa: opportunities and challenges
in Trends in Microbiology
Eaglesfield R
(2021)
Targeting and Insertion of Membrane Proteins in Mitochondria.
in Frontiers in cell and developmental biology
Geldon S
(2021)
Redox-Mediated Regulation of Mitochondrial Biogenesis, Dynamics, and Respiratory Chain Assembly in Yeast and Human Cells.
in Frontiers in cell and developmental biology
Hoare D
(2024)
Realtime monitoring of thrombus formation in vivo using a self-reporting vascular access graft.
in Communications medicine
Kirimi MT
(2024)
Detection of Blood Clots Using a Whole Stent as an Active Implantable Biosensor.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Ledahawsky LM
(2022)
The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo.
in The FEBS journal
Liang X
(2022)
A Neuromorphic Model With Delay-Based Reservoir for Continuous Ventricular Heartbeat Detection.
in IEEE transactions on bio-medical engineering
| Description | Contribution to Tanzanian policy documents informed by key findings from the SNAP-AMR project |
| Geographic Reach | Africa |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | GUMI Symposium - All Party Parliamentary Group (APPG) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Description | Evaluating novel mutant-selective PDE4D PROTACs for the treatment of Acrodysostosis Type 2 |
| Amount | £870,759 (GBP) |
| Funding ID | 870759 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2023 |
| End | 11/2026 |
| Description | KCL MAISI - John Mercer - Regulatory approvals required for VascuGraft |
| Amount | £50,000 (GBP) |
| Organisation | King's College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2025 |
| Description | Kevin Rattigan - Therapeutic enzyme to exploit tyrosine dependency in leukaemia |
| Amount | £40,765 (GBP) |
| Funding ID | 22-23-059 |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Kevin Rattigan - Therapeutic enzyme to exploit tyrosine dependency in leukaemia |
| Amount | £20,000 (GBP) |
| Funding ID | S22-15 |
| Organisation | Tenovus Cancer Care |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Prof. George Baillie - 5th Generation CAR-T Cell Therapy for Prostate Cancer |
| Amount | £20,000 (GBP) |
| Organisation | Philips Healthcare |
| Sector | Private |
| Country | Netherlands |
| Start | 09/2023 |
| End | 10/2026 |
| Description | Prof. George Baillie - Development of PDE4 PROTACS |
| Amount | £481,088 (GBP) |
| Organisation | BioTheryX |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Risk stratification of HPV in self-taken vaginal samples - a potential molecular solution to cervical screening |
| Amount | £297,357 (GBP) |
| Funding ID | TCS/22/24 |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Scottish Enterprise - Market assessment for diagnostics application (Mitotargin) - Kostas Tokatlidis |
| Amount | £5,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Scottish Enterprise HGSP Follow-on funding - Dr. Connor Blair |
| Amount | £200,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Scottish Enterprise HGSP Opportunity Qualification grant |
| Amount | £75,000 (GBP) |
| Funding ID | PS730591C |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 01/2023 |
| Description | Scottish Enterprise High Growth Spin Out - Philips Healthcare Round 2 - John Mercer/VascuSens |
| Amount | $615,000 (USD) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Scottish Enterprise High Growth Spin Out award - John Mercer |
| Amount | £75,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2024 |
| Description | Scottish Enterprise POC application - IMMUNOSTATx - Brewer and Cattanach |
| Amount | £69,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Title | Dataset of four key proteins involved in mitochondria biogenesis |
| Description | Dataset of four key proteins involved in mitochondria biogenesis (expression profiles) in over 300 cancer cell lines (in collaboration with EUROFINS). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | IP generated. |
| Description | Biotheryx collaboration established GB |
| Organisation | BioTheryX |
| Country | United States |
| Sector | Private |
| PI Contribution | University expertise, training and hosting for students that collaborate between university and industry partners. |
| Collaborator Contribution | Thanks to the recent visit (19/02/2022 - 24 /02/2022) funded by this award, co-funding was secured for two more PhD places. Biotheryx have agreed to co-fund one MRC iCASE PhD place on the College's MRC DTP in Precision Medicine (15/09/2022 start) and also co-fund one Medical Research Scotland PhD place (01/10/2022 start). This will maintain and strengthen the link between Biotheryx and Glasgow University and allow further development of the research plan. |
| Impact | Patient group links and fee for service agreement has been established. |
| Start Year | 2022 |
| Description | Collaboration with Jerry Colca from the Metabolic Solutions Development Company (MSDC) - Vignir Helgason |
| Organisation | Metabolic Solutions Development Company |
| Country | United States |
| Sector | Private |
| PI Contribution | In partnership with MSDC and larger industry partner(s) to take forward commercial exploitation |
| Collaborator Contribution | In-kind support (£30k R&D, £225 Jerry Colca/MSDC) |
| Impact | None yet |
| Start Year | 2023 |
| Description | Lily Foundation - public sector collaboration - Kostas Tokatlidis |
| Organisation | The Lily Foundation |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Mitotargin project |
| Collaborator Contribution | Lily Foundation family weekend (2 workshops). |
| Impact | None yet |
| Start Year | 2022 |
| Description | MAISI (King's College London) - VascuGraft: manufacture of active medical devices and implants - JM |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept, design and testing of VascuGraft device |
| Collaborator Contribution | Support the development of a human grade device |
| Impact | None yet |
| Start Year | 2022 |
| Description | Novartis commercial collaboration - Vignir Helgason |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | Working closely pre-clinical and clinical development teams in Novartis Pharmaceuticals |
| Collaborator Contribution | Working closely pre-clinical and clinical development teams in Novartis Pharmaceuticals |
| Impact | None yet |
| Start Year | 2024 |
| Description | Prof. George Baillie - 5th Generation CAR-T Cell Therapy for Prostate Cancer |
| Organisation | Philips Healthcare |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | Principal investigator, concept, experimental design |
| Collaborator Contribution | Philips have agreed to co-fund an MRC iCASE PhD studentship (MVLS DTP in Precision Medicine) starting in Oct 2023. (£20K funding : £100K in-kind) in this area. |
| Impact | None yet |
| Start Year | 2023 |
| Title | Advanced CART treatment of prostate cancer |
| Description | 5th Generation CAR-T Cell Therapy for Prostate Cancer |
| IP Reference | 2022ID01207 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | none |
| Title | Connor Blair / Disruptyx: Lead allosteric c-RAF inhibitor, DRx-170 |
| Description | Utilising funding support from a Scottish Enterprise HGSP Opportunity Qualification grant, and the continued support from University of Glasgow's RSIO, we have filed a patent application on DRx-170 (our lead allosteric c-RAF inhibitor). |
| IP Reference | GB2300853.5 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | None yet |
| Title | Container with adjustable wheel assembly |
| Description | A container, especially a wheeled refuse container, comprises a body made up of sidewalls 12 and a base 16 and a wheel assembly made up of an axle rod 52 and at least one wheel 46 connected thereto, said wheel assembly being adjustable mounted on the underside of the container to move between an inboard position relatively close to the centre of the base or the vertical centreline of the container and an outboard position relatively distant from the centre of the base or the vertical centreline. The mounting may take the form of at least one slot 30 in at least one flange 28, 29, which slot receives the axle rod, said slot having inboard 32 and outboard 34 ends, which ends may be provided with protrusions 36, 38 to entrap the axle rod at the ends. The slot may be J-shaped. The axle rod may have a wheel affixed to each end thereof. With the wheel assembly in its inboard position the container may be nested with similar containers, in the outboard position the tipping stability of the container is enhanced. |
| IP Reference | GB2309672 |
| Protection | Patent / Patent application |
| Year Protection Granted | 1997 |
| Licensed | No |
| Impact | None yet |
| Title | Dr John Mercer: VascuGraft - SYSTEM AND METHOD FOR CELL CHARACTERISATION IN BIOLOGICAL TISSUE |
| Description | The patent was published on 26th Jan 2023 No US-2023-0023897-A1 and the team have undertaken an IP audit of all of technical know-how to identify new protectable elements. |
| IP Reference | US-2023-0023897-A1 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | None yet |
| Title | Mitotargin: mitochondria-targeted peptide inhibitor technology - Kostas Tokatlidis |
| Description | As a novel anticancer therapy, Mitotargin molecules deliver covalently linked therapeutic cargoes to the mitochondria. We have demonstrated payloads covalently attached to Mitotargin, such as small molecules and other peptides. Ongoing studies aim to transport small proteins. For diseases related to the mitochondria, the compounds are dual-functional, not just as cell penetrating peptides, but also mitochondrion specific. We have shown this interesting dual property of cell penetration across the plasma membrane and specific targeting to the mitochondria in multiple cell types. |
| IP Reference | GB 2103243.8 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | None yet |
| Title | Mitotargin: mitochondria-targeted peptide inhibitor technology - Kostas Tokatlidis |
| Description | As a novel anticancer therapy, Mitotargin molecules deliver covalently linked therapeutic cargoes to the mitochondria. We have demonstrated payloads covalently attached to Mitotargin, such as small molecules and other peptides. Ongoing studies aim to transport small proteins. For diseases related to the mitochondria, the compounds are dual-functional, not just as cell penetrating peptides, but also mitochondrion specific. We have shown this interesting dual property of cell penetration across the plasma membrane and specific targeting to the mitochondria in multiple cell types. |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | 2021 |
| Licensed | No |
| Impact | None Yet |
| Title | System and method for cell characterisation in biological tissue - John Mercer |
| Description | System and method for cell characterisation in biological tissue - VascuSens/VascuGraft |
| IP Reference | US-17/443410 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | None yet |
| Title | Vignir Helgason - patent GB2210503.5 |
| Description | the use of MSDC-0160 in combination with TKI for treating CML patients |
| IP Reference | GB2210503.5 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | None yet |
| Title | Design and synthesis of CAR construct with anti-PSMA as a recognition region targeting tumour antigen plus the expression of PDE4 - George Baillie/Connor Blair |
| Description | Design and synthesis of CAR construct with anti-PSMA as a recognition region targeting tumour antigen plus the expression of PDE4 |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2023 |
| Development Status | Under active development/distribution |
| Impact | None yet |
| Company Name | Glox Therapeutics |
| Description | Glox Therapeutics develops precision antibiotics aiming to target drug-resistant pathogenic bacteria. |
| Year Established | 2023 |
| Impact | None yet |
| Website | https://gloxtherapeutics.com/ |
| Company Name | Disruptyx Therapeutics Limited |
| Description | The Scottish Science Advisory Council provides independent advice and recommendations on science strategy, policy and priorities to the Scottish Government, supporting Scotland's status as a science and innovation nation. |
| Year Established | 2022 |
| Impact | None yet |
| Website | http://www.scottishscience.org.uk/ |
| Description | AMR communication materials developed for engaging a wide range of stakeholders in Tanzania |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | As part of our research dissemination plan, several AMR communication materials were developed to facilitate engagement with a wide range of stakeholders. These materials were used both for dissemination activities related to this award and for an antimicrobial resistance symposium organised to commemorate World Antimicrobial Awareness Week (WAAW) 2022 (18th to 24th of November). These include a SNAP-AMR research summary brief; 5 research posters detailing key results and health messages deriving from the SNAP-AMR project, and how these feed into NAP objectives; and a booklet of presentations slides for engagement activity 1 above detailing fundamental information on AMR and associated risk and prevention practices. The 4-page research summary brief and posters were disseminated to research partner institutions in Tanzania: The Catholic University of Health and Allied Sciences; the Kilimanjaro Clinical Research Institute and the Nelson Mandela African Institute of Science and Technology. The presentation handouts were used as an aid during the workshops detailed in the first engagement activity described above and subsequently disseminated to community members and health providers at the end of each workshop. Contributions to the WAAW scientific symposium included oral presentations of SNAP-AMR research findings by Tanzanian members of the team. |
| Year(s) Of Engagement Activity | 2022,2023 |
| Description | Connor Blair: Disruptyx Video Case Study |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | This work was recently documented as a video case study at the University of Glasgow's IAA celebration event 2023. This video case study highlighted the key support UofG IAA funding has provided how it has allowed for novel/impactful research to be carried out by Connor Blair's research group. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=7HLozgPNnh8 |
| Description | Digital Health Validation Lab (DHVL) - Launch Event (8th November 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Successful DHVL launch November 8th 2023 was directly related to feedback and insights garnered through this project's networking event. https://www.gla.ac.uk/colleges/mvls/livinglab/newsevents/headline_998491_en.html https://www.gla.ac.uk/colleges/mvls/livinglab/newsevents/headline_1021953_en.html |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.gla.ac.uk/colleges/mvls/livinglab/newsevents/headline_1021953_en.html |
| Description | Dr Jo Halliday: Human brucellosis policy in Tanzania - meeting with Chief Pharmacist, Dodoma, Tanzania |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Meeting with Chief Pharmacist - 2nd Feb 2023, Dodoma Tanzania; 5 people directly involved (meeting planned in March to involve ~29 members of national committee) with local to national reach. Primary audience of policymakers. |
| Year(s) Of Engagement Activity | 2023 |
| Description | GUMI Symposium |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | GUMI symposium had 85 registered attendees. These were from the University of Glasgow and NHS Greater Glasgow and Clyde. Audience was primarily academics but also clinicians and a couple of industry people. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.gla.ac.uk/research/az/gumi/# |
| Description | Prof. Kostas Tokatlidis - Lily Foundation family weekend |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | PPIE (Public patient involevement and engagement): Prof Tokatlidis was invited as a speaker in the Lily Foundation family weekend (the largest UK based mito-patient charity) alongside the RA Fara van der Schans. Prof Tokatlidis led 2 focused workshops in the meeting and Fara van der Schans another one. Disemination after this on social media channels (twitter of Tokatlidis Lab and the Lily Foundation); https://www.youtube.com/watch?v=mmAyUv30zPI ; https://www.youtube.com/watch?v=ejQaeEqDn7Y |
| Year(s) Of Engagement Activity | 2020,2021 |
| URL | https://www.youtube.com/watch?v=mmAyUv30zPI |
| Description | Prof. Kostas Tokatlidis - Mitotargin case study video |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Kostas Tokatlidis (Cathcart Chair of Biochemistry, University of Glasgow) and Dr Keith Wreggett (Biotech Consultant, InnoSpective) discuss the Mitotargin Project; an innovative translational project to develop therapeutic and diagnostic applications through research into the mitochondria. Mitotargin Translational Project funded through the Wellcome Trust Translational Partnership Award, grant ref. 219390/Z/19/Z, BBSRC Impact Accelerator Account ref. BB/S506734/1, MRC Proximity to Discovery award ref. MC_PC_17190 and MRC Confidence in Concept Award, grant ref. MC_PC_18048 and MC_PC_19039. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=1YJLB1nVnO4 |
| Description | Prof. Sheila Graham: Scottish HPV Investigators' network meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Scottish HPV Investigators' network. ~50 people. National. Clinicians and clinical scientists. 2022. May 2023 meeting in planning. Information dissemination. Blog and twitter feed planned on 4 March, International HPV Awareness Day to advertise this and the new CSO project. |
| Year(s) Of Engagement Activity | 2022,2023 |
| URL | https://shine.ed.ac.uk/shine-meetings-and-relevant-events/meeting-archive/shine-meeting-2022 |
| Description | SNAP-AMR community workshops for raising awareness on AMR (Kilimanjaro, Arusha and Mwanza Regions of Tanzania) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Six two-day workshops were conducted in three regions in northern Tanzania (two workshops per region) representative of predominant livestock-production systems in East Africa (agro-pastoral, pastoral and rural smallholder) in order to raise awareness on AMR. The workshops were conducted with community members (including community leaders and patient/farmers) and community-based health providers (such as human drug sellers, animal drug sellers, nurses, clinical officers and traditional healers). The workshops covered topics relating to: 1) What micro-organisms are; 2) What diseases they cause; 3) How these diseases are treated; 4) Drug efficacy; 5) Drug resistance; 6) How resistance spreads; 7) How human behaviours contribute to resistance; and 8) How it can be prevented. The workshops also included discussion sessions with participants on topics 5 - 8 with a view at identifying main areas for interventions that should be taken forward. |
| Year(s) Of Engagement Activity | 2023 |
| Description | SNAP-AMR team contributions at the antimicrobial resistance Multi-sectoral Coordination Committee (MCC) meeting (Dar es Salaam, Tanzania) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Nine members of the SNAP-AMR team attended the 21st meeting of the antimicrobial resistance multi-sectoral coordination committee in Dar es Salaam, Tanzania on the 26th and 27th of September 2021. The team compiled a comprehensive report in preparation for the meeting detailing key findings from the team's research activities conducted since 2018. These results were also presented at the meeting. These results have fed into each objective of the National Action Plan (NAP) on AMR which are: Objective 1: Creating Awareness and Understanding; Objective 2: Surveillance and Research; Objective 3: Infection Prevention and Control; Objective 4: Optimise the Use of Antimicrobial Agents in Human, Animal and Plant Health; and Objective 5: Economic Case. The evidence-informed priorities identified by the team and MCC members were subsequently fed into the most recent 'Implementation Status report of the National Action Plan on Antimicrobial Resistance 2017-2022' and the 'National Action Plan on Antimicrobial Resistance 2023-2028.' |
| Year(s) Of Engagement Activity | 2021,2022 |
| Description | SNAP-AMR workshop in Dar es Salaam, Tanzania |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Three members of the SNAP-AMR Glasgow-based team hosted a three-day workshop in Dar es Salaam, Tanzania during February 20th to 22nd 2024. The meeting enabled discussions to (1) "map" the impact generated by SNAP-AMR research and the evidence needed to demonstrate this; (2) co-produce future research priorities to support the delivery of the new Tanzanian National Action Plan for AMR (2023-2028), whose development SNAP-AMR supported; (3) enable discussions to link SNAP-AMR research in Tanzania with other well-established platforms in East Africa, specifically the Digital One Health lab ([https://digital-one-health.github.io)]https://digital-one-health.github.io) at the Roslin Institute (University of Edinburgh). The Digital One Health lab is developing a digital One Health framework focusing on AMR in East Africa to integrate data for public health decision making; and (4) review an AMR communication toolkit developed as part of SNAP-AMR to support the Tanzanian government in the design and implementation of communication campaigns to raise AMR awareness amongst healthcare providers and the public. The toolkit was revised during this meeting and subsequently presented to the broader MCC-AMR at a meeting in Dodoma on February 29th 2024. Further steps regarding the toolkit will be to identify stakeholders who would benefit from this resource and distribute it to these in June 2024. |
| Year(s) Of Engagement Activity | 2024 |